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comments and questions. I would like to begin by addressing your
question regarding our multidisciplinary approach. I cannot over-
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DrMarc A. Passman (Birmingham, Ala). Dr Lidsky and his
fellow authors from Duke University Medical Center should be
congratulated on addressing a topic that, while within the scope
of our vascular specialty, has been of variable interest to most
vascular surgeons in clinical practice. Vascular malformations
represent uncommon, complex vascular problems that range in
severity, are variable in pattern and presentation, and are diffi-
cult to treat. However, with expansion of endovascular tech-
niques within vascular surgery to include small vessel catheter
access, embolization skills, and advanced ultrasound guided
sclerotherapy, vascular surgeons are expanding their practice to
include these challenging problems. This study reviews the
multidisciplinary approach used to treat congenital vascular
malformations at a single academic center. Using a simplified
classification and grading system, outcomes for 136 vascular
malformations in 135 patients, 77% representing low flow and
23% high-flow malformations, are reported with significant
improvement in 84% and 88%, respectively.
A few questions: First, in this study, outcomes are assessed
using a subjective nonvalidated grading system for a problem
that is difficult to quantify, not curative with embolization or
sclerotherapy, oftentimes requires multiple treatments, and for
a study group where curative resection was only occasionally
used. So the strength of your results is somewhat weakened by
those variables and your analysis dependent of this subjective
grading system. Plus, most patients required multiple treat-
ments. Was there any additional imaging like the dynamic
contrast enhanced magnetic resonance imaging on at least some of
your patients between multiple treatment sessions that could be used
as a more objective outcome measure? Second, while the need for a
multidisciplinary approach is important, how do you best assess the
impact of having these other specialties involved in the care of vascular
malformations to better justify the need for the multidisciplinary
approach you are advocating. Your team consisted of vascular sur-
geons, pediatric surgeons, adult and pediatric hematologists, adult
and pediatric dermatologists, adult and pediatric ophthalmologists,
plastic surgeons, and diagnostic and interventional radiologists.
That’s a lot of firepower. Finding interested parties, managing cross-
turf issues, and coming up with consensus treatment recommenda-
tions is almost more challenging than actually treating the malforma-
tion. I realize Dr Shortell can be a very convincing influence, but for
most of us, it is difficult to get these other specialities interested in
participating in a cooperative effort. Can you provide a little more
insight on how you brought all of this expertise together and how you
balance these different interests in a unified program?
Again, I appreciate the opportunity to discuss this paper and
congratulate the authors on their work.
Dr Michael E. Lidsky. Thank you, Dr Passman, for yourmphasize enough the role of an inspiring team leader, such as Dr
hortell, to motivate other specialists to participate in discussions.
hese team discussions focus on specific cases so as to offer
omplex patients the most appropriate and patient-driven care. By
ombining the expertise of each individual specialist, therapy can
e individualized so as to optimize outcomes. When interventions
re warranted, vascular surgery performs the majority of transcutane-
us sclerotherapy procedures, while interventional radiology per-
orms the majority of transarterial procedures as well as fluoroscopi-
ally guided cases. Plastic surgery plays a significant role in lesions of
he head and neck, especially when lesions are disfiguring.Orthopedic
urgery performs many of the primary or secondary excisions of the
xtremities. As I mentioned, being able to individualize the treat-
ents based on the patient’s needs and the lesion type have helped us
chieve the success that I demonstrated today.
Regarding your question pertaining to subjectively evaluating
atients during their course of treatment, I want to clarify that the
valuation data shown here were based on documentation and
valuation at the time of our review. Some patients included in the
ata presented today are still undergoing treatment, and will likely
ontinue to improve. Patients are routinely evaluated at each
ollow-up appointment or treatment session, which provides an
pportunity to find out how the patients think they are doing and
f we are reaching their expectations and goals. Again, these goals
re derived by both the patient and primary treating team physician
t the time of initial evaluation. Given that many vascular malfor-
ations are palliated with treatment and not necessarily cured,
rriving at realistic goals and expectations with the patient, facili-
ated by the physician being transparent with regard to their
xperience, is important. In doing so, the patient will understand
he reality of the lesion and what to expect with treatment, how
uickly it can get better, and how much improvement they can
xpect.
To answer your final question regarding repeat imaging, our
roup does not routinely reimage with dynamic contrast enhanced
agnetic resonance imaging, unless there is concern for unpredict-
ble changes in flow quality during the treatment course. Critical
ualitative data are obtained at the time of the initial diagnostic
ynamic contrast enhanced magnetic resonance imaging, such as
ow quality, lesion extent, and involvement of multiple tissue
lanes and/or vital structures. To take your concern one step
urther, there may be a role for reimaging to assess response to
herapy. While the outcomes presented today are primarily subjec-
ive assessments by the patient and physician, Blaise and colleagues
rom France routinely evaluate lesions with ultrasound in the
ostprocedural setting to show that the lesions have sclerosed.
hile this type of objective evidence of therapeutic efficacy wouldtrengthen our results, we do not think it currently plays a role in
he clinical setting.
